Cancer Research UK and Stitch partner to understand and improve the patient experience on clinical trials

Cancer Research UK and Stitch partner to understand and improve the patient experience on clinical trials

Share this article
LinkedinFacebookTwitter

Cancer Research UK announced today that they are partnering with Stitch to improve the patient experience on their clinical trials. By working with Stitch to help patients manage their trial journey and capture their feedback, Cancer Research UK aims to improve the quality of the patient clinical trial experience.

Cancer Research UK announced today that they are partnering with Stitch to improve the patient experience on their clinical trials. By working with Stitch to help patients manage their trial journey and capture their feedback, Cancer Research UK aims to improve the quality of the patient clinical trial experience.

Nigel Blackburn, Director of Drug Development at Cancer Research UK says:

We are committed to involving patients and the public in our research to maximise impact. Partnering with Stitch creates a unique opportunity for us to hear directly from patients throughout their clinical trial journey so we can apply their insights to design more patient-centric clinical trials. So many of us are routinely using apps on our mobile devices as part of our normal daily lives, so it is exciting that this technology can now be tailored to meet the needs of cancer patients during their time on a clinical trial.

As part of the collaboration, Cancer Research UK and Stitch are working directly with people affected by cancer to co-create the best possible experience for patients. The Cancer Research UK Centre for Drug Development plans to have patients on their studies using the Stitch platform later this year.

The feedback that Stitch collects from patients will be used to improve future Cancer Research UK studies, making them better for patients, and more effective at investigating novel treatments.

Dr Blackburn explains that:

Working with Stitch to develop an application specifically for clinical trial patients is an innovative next step in our patient involvement activities. We intend to co-create the application with the Cancer Research UK patient involvement network, considering the best ways to support patients with clinical trial logistics and designing appropriate feedback questionnaires for all stages of the patient journey on a clinical trial.

Jonathan Moshinsky, CEO of Stitch, says:

It’s a privilege to work with Cancer Research UK. Their continued focus on patient experience makes them a perfect partner for us, and we’re humbled to be able to support them on their mission to beat cancer sooner.

About Cancer Research UK

• Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information.

• Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.

• Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.

• Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034.

• Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses.

• Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.

For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit https://www.cancerresearchuk.org. Follow us on Twitter and Facebook.

About Cancer Research UK’s Centre for Drug Development

Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 25 years, taking over 140 potential new anti-cancer agents into clinical trials in patients. It currently has a portfolio of 21 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials. Six of these new agents have made it to market including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase III trials. www.cruk.org.uk/cdd

About Stitch

Stitch is the retention platform for clinical trials. Stitch improves patient experience by making it easy for patients to manage their trial journey and share their feedback. This feedback enables faster, more patient-centric trials, with better retention. For more information, visit stitchhealth.co